Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced the completion of its evaluation of the 2025 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns”, and approved a corresponding plan for 2026.

The company reported that revenue from its industrial segment rose 8.64 % year-on-year in 2025, while total operating revenue fell to about 0.98 billion Singapore dollars after the divestment of its pharmaceutical commercial segment.

Shareholder distributions remained a priority. A July 2025 cash dividend of approximately 197 million Singapore dollars was paid for FY2024, and a further 377 million Singapore dollars was distributed in February 2026 for the first three quarters of FY2025. A shareholder return plan covering 2026-2028, together with the FY2025 profit-distribution proposal, will be tabled for shareholder approval.

Key 2026 initiatives include reinforcing nine regional branches, expanding core product marketing through medical, retail, e-commerce and direct-to-consumer channels, and launching a nationwide cardiovascular public-welfare campaign. Operationally, the company will broaden raw-material traceability bases, upgrade a three-tier quality-control system, enhance supply-chain flexibility and continue its AI partnership with Huawei Cloud.

Governance measures completed in 2025—such as abolishing the Supervisory Committee, strengthening audit-committee oversight and renaming the Strategy Committee to encompass sustainability—will be followed in 2026 by new director and senior-management remuneration policies aligned with China’s Code of Corporate Governance of Listed Companies.

The group stated that forward-looking plans may be affected by macro-economic or industry changes and do not constitute binding commitments to investors.